Cargando…
Exploration of the immunogenetic landscape of hyperprogressive disease after combined immunotherapy in cancer patients
The immune-genetic changes that occur in cancer patients experiencing hyperprogressive disease (HPD) during combined immunotherapy are unclear. In this study, HPD patients with pre- and post-HPD samples and non-HPD patients with solid tumors were molecularly characterized by genetic and tumor immune...
Autores principales: | Gong, Caifeng, Zhang, Wen, Sun, Yongkun, Shou, Jianzhong, Jiang, Zhichao, Liu, Tianyi, Wang, Shengzhou, Liu, Jun, Sun, Ying, Zhou, Aiping |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225883/ https://www.ncbi.nlm.nih.gov/pubmed/37255657 http://dx.doi.org/10.1016/j.isci.2023.106720 |
Ejemplares similares
-
Hyperprogression under Immune Checkpoint Inhibitor: a potential role for germinal immunogenetics
por: Refae, Sadal, et al.
Publicado: (2020) -
Hyperprogression under Immunotherapy
por: Frelaut, Maxime, et al.
Publicado: (2019) -
Hyperprogression after immunotherapy
por: Abbas, Waseem, et al.
Publicado: (2019) -
Author Correction: Hyperprogression under Immune Checkpoint Inhibitor: a potential role for germinal immunogenetics
por: Refae, Sadal, et al.
Publicado: (2020) -
Nab-paclitaxel plus tegafur gimeracil oteracil potassium capsule (S-1) as first-line treatment for advanced biliary tract adenocarcinoma: a phase 2 clinical trial
por: Zhang, Wen, et al.
Publicado: (2021)